We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+13.92%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
+$104M
Cap. Flow
-$16.3M
Cap. Flow %
-0.99%
Top 10 Hldgs %
51.14%
Holding
80
New
16
Increased
18
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$67.2M
2
ABBV icon
AbbVie
ABBV
+$49.4M
3
BSX icon
Boston Scientific
BSX
+$43.6M
4
UTHR icon
United Therapeutics
UTHR
+$35.4M
5
LLY icon
Eli Lilly
LLY
+$34.4M

Top Sells

Rank Stock Value
1
SYK icon
Stryker
SYK
+$111M
2
MDT icon
Medtronic
MDT
+$50.6M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.6M
4
BPMC
Blueprint Medicines
BPMC
+$23.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 89.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$262M 16.02%
1,550,280
– –
GILD icon
2
Gilead Sciences
GILD
$161B
$116M 7.12%
1,050,308
+631,408
+151% +$67.2M
LLY icon
3
Eli Lilly
LLY
$1.07T
$75.6M 4.63%
97,018
+44,218
+84% +$34.4M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$73.7M 4.51%
694,096
+184,046
+36% +$20M
VERA icon
5
Vera Therapeutics
VERA
$2.54B
$65.8M 4.03%
2,793,987
– –
IWM icon
6
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$53.9M 3.3%
250,000
-100,000
-29% -$20.1M
ABBV icon
7
AbbVie
ABBV
$458B
$49.3M 3.02%
+265,850
New +$49.4M
IBB icon
8
PUT
iShares Biotechnology ETF
IBB
$9.31B
$47.4M 2.9%
+375,000
New +$46M
BSX icon
9
Boston Scientific
BSX
$65.8B
$46.3M 2.83%
+431,200
New +$43.6M
DXCM icon
10
DexCom
DXCM
$27.6B
$45.7M 2.8%
523,694
+127,719
+32% +$10M
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.41B
$45.1M 2.76%
2,147,795
-474,397
-18% -$9.1M
BBIO icon
12
BridgeBio Pharma
BBIO
$16.5B
$42.9M 2.62%
993,093
+258,866
+35% +$9.42M
ISRG icon
13
Intuitive Surgical
ISRG
$121B
$38.4M 2.35%
70,642
+58,658
+489% +$30.7M
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$7B
$37M 2.26%
586,010
+139,171
+31% +$8.52M
AVBP icon
15
ArriVent BioPharma
AVBP
$1.48B
$36.9M 2.26%
1,696,752
– –
ROIV icon
16
Roivant Sciences
ROIV
$25.2B
$34.8M 2.13%
3,088,814
+1,809,304
+141% +$19.6M
SLNO
17
DELISTED
Soleno Therapeutics
SLNO
$34.8M 2.13%
415,219
-69,252
-14% -$5.18M
UTHR icon
18
United Therapeutics
UTHR
$26.3B
$34.1M 2.08%
+118,513
New +$35.4M
INSM icon
19
Insmed
INSM
$23.2B
$31.6M 1.93%
313,923
+9,669
+3% +$739K
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$29.3M 1.79%
548,788
+38,768
+8% +$1.76M
SUPN icon
21
Supernus Pharmaceuticals
SUPN
$2.68B
$25.2M 1.54%
799,253
+278,575
+54% +$8.93M
ANAB icon
22
AnaptysBio
ANAB
$1.6B
$22.9M 1.4%
1,032,362
-127,671
-11% -$2.67M
RAPP
23
Rapport Therapeutics
RAPP
$1.95B
$22.7M 1.39%
1,995,594
– –
QURE icon
24
uniQure
QURE
$2.68B
$21.7M 1.33%
1,558,356
+1,012,585
+186% +$13.6M
MRUS
25
DELISTED
Merus
MRUS
$21.3M 1.3%
+404,562
New +$19M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2025 Portfolio in Review

As of Q2 2025, Sofinnova Investments held 80 positions worth $1.64B, up 6.8% from $1.53B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sofinnova Investments's Q2 2025 filing shows 16 new, 18 increased, 19 reduced and 17 closed positions. Its largest new stake was AbbVie: 265,850 shares worth $49.3M. The largest sale was Stryker, an estimated $111M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier.

  • Sofinnova Investments's largest Q2 2025 buy was AbbVie: 265,850 shares worth $49.3M.
  • Sofinnova Investments added most to Gilead Sciences in Q2 2025, an estimated $67.2M increase.
  • Sofinnova Investments's biggest Q2 2025 reduction was PTC Therapeutics, cutting an estimated $9.66M.
  • Sofinnova Investments fully exited Stryker in Q2 2025, selling an estimated $111M.
  • Sofinnova Investments's ten largest holdings make up 51% of its $1.64B portfolio in Q2 2025.
  • Sofinnova Investments opened 16 new positions and closed 17 in Q2 2025.
  • Sofinnova Investments's portfolio value rose 6.8% quarter-over-quarter to $1.64B.

Based on Sofinnova Investments's 13F filing for Q2 2025, filed 14 Aug 2025.